Advertisement

Topics

UK finds Roche bladder cancer drug too costly for routine use

07:16 EDT 2 Aug 2017 | Reuters

LONDON (Reuters) - Britain's healthcare cost-effectiveness agency NICE has decided Roche's new immunotherapy drug Tecentriq is too expensive to justify its routine use to treat bladder cancer, but still hopes it can be used in certain circumstances. ...

Original Article: UK finds Roche bladder cancer drug too costly for routine use

NEXT ARTICLE

More From BioPortfolio on "UK finds Roche bladder cancer drug too costly for routine use"

Quick Search
Advertisement
 

Relevant Topics

Healthcare
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...